To investigate whether LAP2α down-regulation is a common progeria-related phenotype, we examined LAP2α and progerin levels in two other patient cell lines derived from younger patients (HGPS 1 and HGPS 2) in addition to the one analyzed before, derived from an older patient (HGPS 3), at mid-passage (p11–p13) by double immunofluorescence. This evidence concerns the gene LMNA and progeroid syndrome.